December 7, 2023
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
November 9, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 3, 2023
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
October 31, 2023
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
September 27, 2023
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 5, 2023
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
September 5, 2023
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
August 14, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
August 3, 2023
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
May 25, 2023
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
Displaying 1 - 10 of 16